NRAS and Miyoshi myopathy: With minor variation among the different studies, the reported mutation incidence is 22–25% for KRAS, 20–25% for NRAS and 6–15% for BRAF, with up to 50% of newly diagnosed MM cases affected by RAS-MAPK pathway aberration on the whole [45,46,47,124].